株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

早産 (子宮収縮抑制) :パイプライン製品の分析

Premature Labor (Tocolysis) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 245999
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.82円で換算しております。
Back to Top
早産 (子宮収縮抑制) :パイプライン製品の分析 Premature Labor (Tocolysis) - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 49 Pages
概要

早産 (早期分娩) は「妊娠後36週間を経ずに分娩が始まること」と定義されています。主な症状として、骨盤・下腹部への圧迫感や、軽度の膣部痙攣、下痢、膣出血、持続的で重い腰痛などが挙げられます。主な治療薬として、コルチコステロイドや子宮収縮抑制剤などがあります。

当レポートでは、世界各国での早期分娩 (陣痛抑制) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要 (製品概要、標的、作用機序、研究開発 (R&D) の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 調査範囲

早産 (子宮収縮抑制);概要

治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AMAG Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Juniper Pharmaceuticals Inc
  • キッセイ薬品工業
  • Lipocine Inc
  • ObsEva SA

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9115IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2017, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape.

Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premature Labor (Tocolysis) (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premature Labor (Tocolysis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Premature Labor (Tocolysis) - Overview
    • Premature Labor (Tocolysis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Premature Labor (Tocolysis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
    • AMAG Pharmaceuticals Inc
    • GlaxoSmithKline Plc
    • Juniper Pharmaceuticals Inc
    • Kissei Pharmaceutical Co Ltd
    • Lipocine Inc
    • ObsEva SA
  • Premature Labor (Tocolysis) - Drug Profiles
    • bedoradrine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyprogesterone caproate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyprogesterone caproate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBE-022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • progesterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • retosiban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Premature Labor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Premature Labor (Tocolysis) - Dormant Projects
  • Premature Labor (Tocolysis) - Discontinued Products
  • Premature Labor (Tocolysis) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 02, 2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration
      • Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
      • Jan 09, 2017: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
      • Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena
      • Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor
      • Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
      • Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
      • Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
      • Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301
      • Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena
      • Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)
      • Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor
      • May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena
      • May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth
      • Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Premature Labor (Tocolysis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals Inc, H1 2017
  • Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals Inc, H1 2017
  • Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, H1 2017
  • Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2017
  • Premature Labor (Tocolysis) - Dormant Projects, H1 2017
  • Premature Labor (Tocolysis) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Premature Labor (Tocolysis), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top